Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 22
Filtrar
3.
Indian J Dermatol Venereol Leprol ; 87(2): 176-189, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33769755

RESUMO

Xeroderma pigmentosum is a rare hereditary autosomal recessive genodermatosis. At present, there are many treatment options for xeroderma pigmentosum, covering medical/procedural, surgical and combined modalities. However, the quality of these interventions has not been assessed. Our study aimed to perform a systematic review of the literature regarding the treatment of xeroderma pigmentosum. Multiple medical databases were accessed with the Medical Subject Headings terms; "xeroderma pigmentosum," "therapeutics" and "surgical procedures, operative" from January 2000 to April 2019, including articles published in Portuguese, Spanish and English (PROSPERO-CRD42018114858). Two hundred and ninety-eight studies were found in the databases researched, of which, after applying the inclusion criteria, only 33 studies remained. The 33 complete articles were read by three of the authors, having been found: 16 reported medical/procedural and 17 reported surgical treatments. Only one clinical study presented a good level of evidence (EL: 2): a randomized clinical trial using a T4 endonuclease V (T4N5) liposome lotion which reduced the development of skin lesions in patients with xeroderma pigmentosum. Amongst surgical modalities, all studies presented low evidence level (EL: 4). Three illustrative cases are also presented, to emphasize the multiple number of times that surgical modalities may be required in these patients. The therapeutic modalities, both clinical and surgical, for xeroderma pigmentosum presented a low level of scientific evidence which did not allow meta-analysis. More therapeutic studies, both clinical and surgical, with better scientific evidence are needed.


Assuntos
Neoplasias Cutâneas/terapia , Xeroderma Pigmentoso/terapia , Antineoplásicos/uso terapêutico , Procedimentos Cirúrgicos Dermatológicos , Fluoruracila/uso terapêutico , Humanos , Imiquimode/uso terapêutico , Pomadas , Fotoquimioterapia
5.
Indian J Dermatol Venereol Leprol ; 87(5): 666-670, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-31650979

RESUMO

BACKGROUND: Studies comparing head-to-head treatment modalities for anogenital warts are lacking. AIM: We sought to compare a short, 8-week course of imiquimod 5% cream to versus the standard 4 week course of podophyllotoxin in the treatment of anogenital warts and to assess factors that may affect response to treatment. METHODS: This was a retrospective cohort study. We reviewed medical files of otherwise healthy patients with a first episode of anogenital warts who were treated with either a short, 8-week course of imiquimod or the standard 4-week course of podophyllotoxin. Inverse probability of treatment weighted (IPTW). Logistic regression was employed to evaluate factors that may affect response to therapy. RESULTS: The study included 347 patients. In patients with lesions on dry, keratinized anatomical sites, the complete clearance rates were 7.6% for imiquimod and 27.9% for podophyllotoxin (P < 0.001). In patients with lesions on moist, partially keratinized sites, no difference between the treatments was revealed. Significant predictors of > 50% reduction in wart area were location of lesions [odds ratio (OR) (95% confidence interval (CI)): 3.6 (1.84-7.08), P = 0.0002] for "partially keratinized" versus "keratinized" sites and treatment used [OR (95% CI): 1.79 (1.08-2.97), P = 0.024] for podophyllotoxin versus imiquimod. LIMITATIONS: The retrospective design of the study was a limitation that we mitigated against with the use of IPTW logistic regression. CONCLUSION: A standard 4 week course of Podophyllotoxin was more effective than an 8-week course of imiquimod only for lesions on keratinized sites. Treatment with podophyllotoxin and location of lesions on partially keratinized sites were independent predictors of >50% reduction in wart area.


Assuntos
Doenças do Ânus/tratamento farmacológico , Condiloma Acuminado/tratamento farmacológico , Imiquimode/uso terapêutico , Podofilotoxina/uso terapêutico , Adjuvantes Imunológicos/uso terapêutico , Adulto , Estudos de Coortes , Feminino , Humanos , Ceratolíticos/uso terapêutico , Masculino , Pomadas , Estudos Retrospectivos
6.
Indian J Dermatol Venereol Leprol ; 83(5): 569-573, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28731017

RESUMO

BACKGROUND: Palmoplantar psoriasis is often disabling and refractory to conventional therapy. Systemic drugs are indicated in its severe form, but side effects are a concern with their use. Methotrexate is one such systemic drug which is effective and cheap. To reduce systemic toxicity, methotrexate has been tried topically but results have been inconsistent due to poor drug penetration into the skin by passive diffusion. Iontophoresis may enhance its absorption and efficacy. AIM: To evaluate the efficacy and safety of topical methotrexate iontophoresis in comparison with coal tar ointment in the treatment of palmoplantar psoriasis. METHODS: Thirty-one patients with palmar and/or plantar psoriasis were selected for the study and 28 patients completed it. The side having more severe involvement was treated while the other palm/sole served as a control. Iontophoresis using methotrexate solution was carried out on the study palm/sole with the injectable preparation of methotrexate (50 mg/2 ml) once a week for the first 4 weeks and subsequently every two weeks, for a total of six sittings. The control palm/sole was treated with coal tar ointment on other days. Erythema, scaling, induration and fissuring scores were noted in both groups before and after treatment. RESULTS: Both study and control groups showed decreases in scores but the reduction was more in the study group, the difference being statistically significant. LIMITATIONS: Drawbacks of our study include the small sample size and the lack of follow-up. The study and control arms were not exactly matched and the study was not blinded. CONCLUSION: Methotrexate iontophoresis was safe and more effective than coal tar ointmentin palmoplantarpsoriasis.


Assuntos
Alcatrão/administração & dosagem , Fármacos Dermatológicos/administração & dosagem , Iontoforese/métodos , Metotrexato/administração & dosagem , Psoríase/diagnóstico , Psoríase/tratamento farmacológico , Adolescente , Adulto , Idoso , Feminino , Pé/patologia , Mãos/patologia , Humanos , Masculino , Pessoa de Meia-Idade , Pomadas , Projetos Piloto , Adulto Jovem
7.
Artigo em Inglês | MEDLINE | ID: mdl-26144851

RESUMO

BACKGROUND: Prolonged and frequent use of topical steroids may lead to decrease in efficacy as well as many local adverse effects. Stratum corneum has a unique property of reservoir effect. AIMS: To study the reservoir effect of topical steroids in a steroid-responsive condition which may enable a decrease in the dosing frequency of topical steroids. METHODS: A cross-sectional study design was used. Patients with at least three vitiliginous patches of more than 2 cm 2 present over the trunk or limbs were included. Exclusion criteria were topical or systemic corticosteroid use within the previous 4 weeks, antihistamine use within the previous 7 days, history of any allergy in the past and immunosuppression. Clobetasol propionate cream was applied on the first vitiliginous area (site A) and fluticasone propionate ointment was applied on the second vitiliginous area (site B). The third vitiliginous area, site C (control site) was left without applying any medication. Histamine-induced wheal suppression test was performed on each site, at the same time of the day, on every consecutive day following steroid application, until the values obtained at sites A and B approached those obtained at site C. SPSS software for Windows, version 16.0 was used for statistical analysis. The mean and standard deviation of the various studied parameters were calculated for various treatment groups and compared using analysis of variance (ANOVA) test. RESULTS: Forty patients were included in the study. The average wheal volumes and average erythema sizes at sites A and B were significantly smaller than the corresponding values at site C for up to 5 days after applying medication (P < 0.001). LIMITATIONS: The presence of a cutaneous reservoir of topical steroid was confirmed based on its suppressive effect on the wheal and flare response to histamine. It is not certain that the concentration that suppresses histamine-induced wheal and flare is sufficient for therapeutic efficacy in vitiligo. CONCLUSION: The reservoir effect of topical clobetasol propionate and fluticasone propionate persisted for 5 days in vitiliginous skin. Hence, it may be possible to reduce the frequency of topical steroid application in vitiligo.


Assuntos
Anti-Inflamatórios/metabolismo , Clobetasol/metabolismo , Fluticasona/metabolismo , Vitiligo/tratamento farmacológico , Vitiligo/metabolismo , Administração Cutânea , Adolescente , Adulto , Anti-Inflamatórios/administração & dosagem , Clobetasol/administração & dosagem , Estudos Transversais , Feminino , Fluticasona/administração & dosagem , Histamina/farmacologia , Humanos , Masculino , Pessoa de Meia-Idade , Pomadas/administração & dosagem , Pomadas/metabolismo , Pele/efeitos dos fármacos , Creme para a Pele/administração & dosagem , Creme para a Pele/metabolismo , Taquifilaxia , Adulto Jovem
9.
Artigo em Inglês | MEDLINE | ID: mdl-20445292

RESUMO

Vitiligo is a psychologically devastating condition. Topical therapy is employed as first-line treatment in localized vitiligo. Currently, several topical agents are available in many forms viz. methoxsalen (solution and cream), trioxsalen (solution), corticosteroids (gel, cream, ointment and solution) and calcineurin inhibitors (ointment and cream). Although topical therapy has an important position in vitiligo treatment, side-effects or poor efficacy affect their utility and patient compliance. Novel drug delivery strategies can play a pivotal role in improving the topical delivery of various drugs by enhancing their epidermal localization with a concomitant reduction in their side-effects and improving their effectiveness. The current review emphasizes the potential of various phospholipid based carriers viz. liposomes, transferosomes, ethosomes, lipid emulsions, solid lipid nanoparticles and organogels in optimizing and enhancing the topical delivery of anti-vitiligo agents, whilst reducing the side effects of drugs commonly used in its topical treatment.


Assuntos
Sistemas de Liberação de Medicamentos/tendências , Vitiligo/tratamento farmacológico , Vitiligo/patologia , Administração Tópica , Corticosteroides/administração & dosagem , Animais , Sistemas de Liberação de Medicamentos/métodos , Humanos , Pomadas/administração & dosagem
10.
Artigo em Inglês | MEDLINE | ID: mdl-19052406

RESUMO

BACKGROUND: Topical therapies are the first line of treatment for patients with stable plaque psoriasis affecting a limited body surface area. Though in use for more than a decade, we could not find any reports of studies directly comparing calcipotriol and tazarotene. AIM: To evaluate the comparative efficacy and tolerability of calcipotriol and tazarotene in the treatment of stable plaque psoriasis. METHODS: This was a prospective, right-left side intra-individual parallel 8-week study using calcipotriol 0.005% ointment applied twice daily (right side) versus tazarotene (left side) randomized to either 0.05% (group I) or 0.1% gel (group II) once daily in two groups, each of 10 patients. Efficacy was determined by the assessment of target psoriatic lesions under evaluation by using the severity scale (0-3) of erythema, scaling, and infiltration (ESI score). Evaluation was done at baseline (0 week), 4 weeks, and 8 weeks of treatment. At the end of 8 weeks, patients with more than 75% reduction in ESI score were considered to have marked improvement; 51% to 75%, moderate improvement; 26% to 50%, minimal improvement; and less than 25%, non-responders. RESULTS: Seventeen patients (9 in group I, 8 in group II) completed the study. In group I, reduction in ESI score was significantly more at both 4 and 8 weeks on sides treated with calcipotriol, producing moderate-to-marked improvement (P<0.05). In group II, improvement was comparable in lesions treated with either calcipotriol or tazarotene (0.1%) at the end of 4 and 8 weeks. Adverse effects noted were mild--in the form of burning, pruritus, and irritation--and were observed more often in the lesions treated with tazarotene as compared to those in the lesions treated with calcipotriol, but the difference was not statistically significant. However, none of the patients discontinued the therapy because of adverse events. CONCLUSION: Topical calcipotriol 0.005% ointment is more effective than tazarotene 0.05% gel; however, its efficacy is comparable to tazarotene 0.1% gel in the treatment of stable plaque psoriasis.


Assuntos
Calcitriol/análogos & derivados , Fármacos Dermatológicos/administração & dosagem , Ácidos Nicotínicos/administração & dosagem , Psoríase/tratamento farmacológico , Administração Tópica , Adolescente , Adulto , Calcitriol/administração & dosagem , Feminino , Géis , Humanos , Masculino , Pomadas , Projetos Piloto , Estudos Prospectivos , Psoríase/patologia , Adulto Jovem
11.
Nihon Hansenbyo Gakkai Zasshi ; 77(3): 211-3, 2008 Sep.
Artigo em Japonês | MEDLINE | ID: mdl-18800642

RESUMO

The causes of skin ulcers in collagen vascular diseases are complicated, and involve peripheral vascular complications, vasculitis, and thrombosis. It is necessary to determine the treatment, such as oral medication, infusion, ointment and surgery after careful consideration of its causes. This review shows skin manifestations of various collagen vascular diseases and the causes of skin ulcers in these diseases.


Assuntos
Doenças do Colágeno/complicações , Úlcera Cutânea/etiologia , Úlcera Cutânea/terapia , Doenças Vasculares/complicações , Alprostadil/administração & dosagem , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais Murinos , Anticoagulantes/administração & dosagem , Síndrome Antifosfolipídica/complicações , Citocinas/administração & dosagem , Globinas/administração & dosagem , Glucocorticoides/administração & dosagem , Humanos , Imunossupressores/administração & dosagem , Pomadas , Troca Plasmática , Pulsoterapia , Rituximab
13.
Artigo em Inglês | MEDLINE | ID: mdl-17319037

RESUMO

BACKGROUND: No controlled data is available till date comparing topical tazarotene and clobetasol in Indian psoriatic patients. OBJECTIVE: The aim was to compare the clinical efficacy of 12 weeks of once-daily tazarotene 0.1% cream with that of once-daily clobetasol propionate 0.05% cream in the treatment of patients with chronic plaque psoriasis. METHODS: About 36 patients with bilaterally symmetrical lesions were enrolled in this double-blind randomized controlled study. A left-right randomized study was conducted. RESULTS: Clobetasol cream was better than tazarotene cream in reducing the erythema throughout the treatment period with statistically significant differences favoring clobetasol at weeks 2, 4, 6 and 8 ( P <0.05). Tazarotene was better in reducing the induration at weeks 2 ( P <0.05), 4, 10 and 12. Clobetasol cream was better in reducing the scaling throughout the treatment period with statistically significant differences favoring clobetasol over the entire treatment period. Treatment success rate was 100% with clobetasol and 88% with tazarotene at the end of week 12 with clobetasol achieving 100% success rate at the end of week 6. Treatment with tazarotene resulted in uniform reduction of plaque elevation and was not associated with the development of hot spots. CONCLUSION: Topical tazarotene 0.1% cream is less effective than topical clobetasol propionate 0.05% cream in the treatment of plaque psoriasis. It has more effect on induration than on erythema and scaling of psoriatic lesions.


Assuntos
Clobetasol/administração & dosagem , Fármacos Dermatológicos/administração & dosagem , Glucocorticoides/administração & dosagem , Ácidos Nicotínicos/administração & dosagem , Psoríase/tratamento farmacológico , Administração Tópica , Adolescente , Adulto , Idoso , Doença Crônica , Clobetasol/efeitos adversos , Clobetasol/uso terapêutico , Fármacos Dermatológicos/efeitos adversos , Fármacos Dermatológicos/uso terapêutico , Método Duplo-Cego , Eritema/tratamento farmacológico , Eritema/patologia , Feminino , Glucocorticoides/efeitos adversos , Glucocorticoides/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Ácidos Nicotínicos/efeitos adversos , Ácidos Nicotínicos/uso terapêutico , Pomadas , Psoríase/patologia , Resultado do Tratamento
14.
Artigo em Inglês | MEDLINE | ID: mdl-17314444

RESUMO

BACKGROUND: Alopecia areata is a recurrent, nonscarring type of hair loss. Different modalities of treatment have been used to induce hair re-growth. AIMS: To determine the efficacy of topical garlic gel in the treatment of alopecia areata. METHODS: Patients were randomly divided into two groups of garlic gel and placebo. The two groups were advised to follow the treatment twice daily, for three months. Both groups received topical application of corticosteroid (betamethasone cream 0.1% in isopropyl alcohol) twice daily. Baseline demographic characteristics and the size of patches, total number of grown hair and number of terminal hair at the end of each month were recorded. Effectiveness was assessed by scoring the results. Statistical analysis was done by means of chi-square and t test. RESULTS: Forty patients met the inclusion criteria and enrolled for the study. The first group (garlic treated) consisted of 20 patients (12 males, 60% and eight females, 40%). The second group (control) consisted of 20 patients (10 males, 50% and 10 females, 50%). At the end of the treatment, good and moderate responses were observed in 19 (95%) and one (5%) patients of the case group respectively, which was significantly better than the control group (P = 0.001). No complication was observed in the patients under study. CONCLUSION: The present study showed that the use of garlic gel significantly added to the therapeutic efficacy of topical betamethasone valerate in alopecia areata and that it can be an effective adjunctive topical therapy for alopecia areata.


Assuntos
Alopecia em Áreas/terapia , Betametasona/análogos & derivados , Alho , Géis , Administração Tópica , Adolescente , Adulto , Alopecia em Áreas/tratamento farmacológico , Betametasona/administração & dosagem , Betametasona/uso terapêutico , Criança , Pré-Escolar , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pomadas , Resultado do Tratamento
15.
Artigo em Inglês | MEDLINE | ID: mdl-17050935

RESUMO

Imiquimod, an immune response modifier, is known to possess both anti-viral and anti-tumor effect. We report our experience of treating a large superficial spreading basal cell carcinoma with 5% imiquimod cream. A 65-year-old male had an asymptomatic, hyperpigmented, slowly progressive, indurated, 3 x 4 cm plaque on the left cheek for two months. Biopsy from the lesion showed features of basal cell carcinoma. The patient was treated with imiquimod 5% cream, topically three times a week for six months with complete resolution of the lesion and without any side-effects. There was no clinical or histological recurrence after three months of stopping the treatment.


Assuntos
Aminoquinolinas/administração & dosagem , Carcinoma Basocelular/tratamento farmacológico , Neoplasias Cutâneas/tratamento farmacológico , Idoso , Carcinoma Basocelular/diagnóstico , Face/patologia , Humanos , Imiquimode , Masculino , Pomadas , Neoplasias Cutâneas/diagnóstico
16.
Int J Lepr Other Mycobact Dis ; 60(2): 269-70, 1992 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-1522368

RESUMO

The use of rifampin and clofazimine ointments alone and in combination over the patches of tuberculoid patients had a beneficial effect. In combination (rifampin and clofazimine), erythema, inflammation, and edema are considerably reduced. For some of the cases with a recent appearance of a patch, the patch completely disappeared. It is suggested that topical therapy with rifampin and clofazimine ointments would be economical and beneficial in tuberculoid leprosy.


Assuntos
Clofazimina/uso terapêutico , Hanseníase Tuberculoide/tratamento farmacológico , Rifampina/uso terapêutico , Dermatite/tratamento farmacológico , Combinação de Medicamentos , Edema/tratamento farmacológico , Eritema/tratamento farmacológico , Humanos , Pomadas
18.
Am J Ophthalmol ; 83(6): 862-5, 1977 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-326055

RESUMO

We tested the corneal penetration of rifampin in four vehicles: dimethylsulfoxide, polyethylene glycol, an ocular lubricant, and as rifampin ointment. We measured drug concentrations in the aqueous humor in rabbits after topical instillation of 1 and 2.5% rifampin according to two dosage schedules. Drug concentrations in the aqueous humor were bactericidal to Mycobacterium leprae. Since leprosy of the cornea, iris, and ciliary body may develop despite standard systemic bacteriostatic treatment, treatment of leprotic involvement of the anterior eye may be enhanced by intensive topical application of rifampin.


Assuntos
Córnea/metabolismo , Rifampina/metabolismo , Administração Tópica , Animais , Humor Aquoso/metabolismo , Clorobutanol , Corpo Ciliar , Dimetil Sulfóxido , Esquema de Medicação , Combinação de Medicamentos , Iris , Ceratite/tratamento farmacológico , Lanolina , Hanseníase/tratamento farmacológico , Óleo Mineral , Mycobacterium leprae/efeitos dos fármacos , Pomadas , Vaselina , Veículos Farmacêuticos , Polietilenoglicóis , Coelhos , Rifampina/administração & dosagem , Rifampina/farmacologia , Doenças da Úvea/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA